Linked Life Data

16125445

Source:http://linkedlifedata.com/resource/pubmed/id/16125445

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2005-9-26
pubmed:abstractText
The evolution of support for the discovery and development of antibacterial (or antibiotic) agents from the larger pharmaceutical companies to the entrepreneur-like small biotechnology companies has been an experiment in the making for the past 15 years. The word 'experiment' is precisely chosen as the outcome is not certain. Many of the antibiotic biotech organizations that were most likely to undertake the task of picking up where large pharmaceutical companies left off have failed to survive, despite their use of outstanding science and their novel approaches to the development of discovery platforms. So this leaves one with the question of 'can biotech deliver the new antibiotics?'.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1369-5274
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
498-503
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Can biotech deliver new antibiotics?
pubmed:affiliation
Department of Infectious Diseases, Merck Research Laboratories, Rahway, NJ 07065, USA. john_barrett@merck.com
pubmed:publicationType
Journal Article, Review